Physician profile
Kyung Chu
NPI 1962724393
$10,616.12
in general payments reported to CMS, 2019-2025
60 companies · $2,960 in 2025
The $2,960 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,418 · 2022: $703 · 2023: $2,170 · 2024: $3,365 · 2025: $2,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,956 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,956.33 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $258.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,587.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,241.07 | 2021-2025 | Lynparza, Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $1,006.86 | 2021-2025 | Opdivo, Reblozyl, Eliquis |
| Tg Therapeutics, INC. | $687.50 | 2021 | |
| Incyte Corporation | $613.18 | 2021-2025 | Jakafi |
| Janssen Biotech, INC. | $583.43 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $459.05 | 2021-2025 | Enhertu |
| Abbvie INC. | $376.50 | 2024-2025 | |
| Glaxosmithkline, LLC. | $307.35 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $269.59 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Seagen INC. | $246.14 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Adaptive Biotechnologies Corporation | $226.69 | 2024-2025 | Clonoseq |
| Pfizer INC. | $197.47 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.07 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.18 | 2023-2025 | Fruzaqla, Alunbrig, Ninlaro |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $175.12 | 2021-2023 | Imbruvica, Epkinly |
| Regeneron Healthcare Solutions, INC. | $142.00 | 2023-2025 | Libtayo |
| Amgen INC. | $134.91 | 2021-2023 | Nplate, Vectibix, Xgeva |
| Mirati Therapeutics, INC. | $132.74 | 2023 | Krazati |
| Lilly USA, LLC | $129.25 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $119.59 | 2022-2025 | Itovebi, Polivy, Tecentriq |
| Karyopharm Therapeutics INC. | $113.80 | 2023-2025 | Xpovio |
| Emd Serono, INC. | $104.39 | 2022-2025 | |
| Genzyme Corporation | $101.89 | 2021-2025 | |
| Eisai INC. | $89.96 | 2022-2024 | |
| Beone Medicines USA, INC. | $82.99 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $75.83 | 2023-2024 | Brukinsa |
| Celgene Corporation | $75.71 | 2022-2024 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $74.99 | 2024 | |
| Gilead Sciences, INC. | $71.54 | 2024 | Trodelvy |
| Geron Corporation | $63.71 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $59.93 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $50.26 | 2022-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $49.22 | 2023-2024 | Monoferric |
| Foundation Medicine, INC. | $46.63 | 2022-2023 | |
| Legend Biotech USA INC. | $36.87 | 2024-2025 | Carvykti |
| Stemline Therapeutics INC. | $33.90 | 2025 | Elzonris, Orserdu |
| Astellas Pharma US INC | $33.73 | 2022-2025 | Vyloy |
| Sobi, INC | $31.51 | 2024-2025 | |
| G1 Therapeutics, INC. | $29.36 | 2023 | Cosela |
| Acrotech Biopharma INC. | $29.19 | 2024 | Beleodaq |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Global Blood Therapeutics, INC. | $28.46 | 2021-2022 | |
| Tempus Ai, INC | $25.87 | 2024 | |
| Acera Surgical, INC. | $25.56 | 2024 | Restrata Wound Matrix |
| Rigel Pharmaceuticals, INC. | $21.58 | 2021 | |
| Dendreon Pharmaceuticals LLC | $20.61 | 2023 | Provenge |
| Verastem, INC. | $20.30 | 2025 | Avmapki Fakzynja Co-Pack |
| Pharmaessentia USA Corporation | $18.39 | 2025 | Besremi |
| Sumitomo Pharma America, INC. | $17.72 | 2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $17.17 | 2025 | Pyrukynd |
| Aimmune Therapeutics, INC. | $16.85 | 2025 | Zenpep |
| Coherus Oncology, INC. | $16.72 | 2023 | |
| Syndax Pharmaceuticals, INC. | $16.00 | 2025 | Niktimvo |
| Genmab U.S., INC. | $14.99 | 2024 | Epkinly |
| Blueprint Medicines Corporation | $14.86 | 2023 | Ayvakit |
| Cti Biopharma Corp. | $14.74 | 2023 | Vonjo |
| Array Biopharma INC | $14.62 | 2025 | Lorbrena |
| Kyowa Kirin, INC. | $12.99 | 2023 | Poteligeo |
| Janssen Pharmaceuticals, INC | $1.06 | 2025 | Darzalex, Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyung Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.